DAHUA-TECHNOLOGY
10.8.2021 15:47:09 CEST | Business Wire | Press release
Dahua Technology, a world leading video-centric smart IoT solution and service provider, has recently released its upgraded Full-color 2.0 Network Cameras that offer brand new functions – including Dual-lens, 4K Color Image, Vari-focal Lens, and AI Features – that can significantly optimize surveillance monitoring and greatly benefit end users in terms of clear and colorful image output.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210810005584/en/
Dual-lens Camera
The upgraded Full-color 2.0 offers dual-lens cameras with large F1.0 aperture, and Dual Light Fusion technology that collects visible color details and lightness information using separate lenses. Equipped with dual CMOS (1/1.8” and 1/2.8”), these cameras provide 36% increase in brightness and 14 times increase in s/n ratio. With pixel-level frame-by-frame mapping, they present high image definition and vivid colors even when the supplementary white light is off, thus reducing light pollution and attraction of insects. Also, its high precision AA (Active Alignment) process ensures that the lenses and sensors are all precisely aligned, allowing it to capture clear color images.
4K Color Image
The 4K network cameras of Full-color 2.0 are equipped with 1/1.2” image sensor. Compared with conventional 8MP camera, this image sensor significantly increases the pixel size by 110%, allowing it to capture real-time 4K color images even under low-light condition. These cameras also boast 42% increase in brightness, and 400% increase in S/N Ratio, providing a clear and high-quality image of the monitored scene.
Vari-focal Lens
The Full-color 2.0 cameras with vari-focal lens offer approx. 5x optical zoom and auto focus function that can maintain clear details even after zooming in. It solves the difficulty in capturing vivid color details of targets during night time or in environments with low illumination, which is a common pain point when using traditional IR vari-focal cameras. It covers narrow indoor spaces and wide outdoor scenarios, which can help ease operation and save time and labor costs.
AI Features
The upgraded Full-color 2.0 network cameras can work with Dahua 5-I/L series NVR, which enables color search for human and vehicle targets (person’s clothes and car exterior) and allows extraction of relevant video footages. It also offers AI Schedule that allows users to set different AI functions according to the time schedule.
By releasing its upgraded Full-color 2.0 Network Cameras, Dahua Technology delivers another artillery of new technologies that can enhance conventional monitoring and meet the various requirements of its customers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005584/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
